On May 15, a federal judge ruled that pharmaceutical companies can’t withhold upfront 340B discounts without federal approval, but also directed HRSA to reconsider Sanofi’s proposed rebate model.
Strategist | strategy-catalyst
Federal judge sides with HRSA on 340B, but leaves door open for drugmaker rebates
Relevant Roles:
Chief Strategy Officers